We are live on
!
Find out more
PIM
Partner Investment Management Portfolio holdings
AUM
$13.9M
1-Year Est. Return
55.92%
This Fund
S&P 500
This Quarter
Est. Return
+5.8%
1 Year Est. Return
+55.92%
3 Year Est. Return
+168.07%
5 Year Est. Return
+301.91%
10 Year Est. Return
–
AUM
$61.1M
AUM Growth
-$266K
(-0.43%)
Cap. Flow
-$9.61M
Cap. Flow
% of AUM
-15.72%
Top 10 Holdings %
Top 10 Hldgs %
31.78%
Holding
108
New
30
Increased
19
Reduced
22
Closed
32
Avg Time Held Equity + Options
2.3
quarters
Top 10 Avg Time Held Equity + Options
0.6
quarters
Top 20 Avg Time Held Equity + Options
1.2
quarters
Avg Time Held Equity only
2.6
quarters
Top 10 Avg Time Held Equity only
1.4
quarters
Top 20 Avg Time Held Equity only
1.2
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$1.88M |
| 2 |
AET
Aetna Inc
AET
|
+$1.8M |
| 3 |
Baxter International
BAX
|
+$1.22M |
| 4 |
McKesson
MCK
|
+$1.04M |
| 5 |
UnitedHealth
UNH
|
+$1.03M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
HCA Healthcare
HCA
|
+$2.28M |
| 2 |
AGN
Allergan plc
AGN
|
+$1.83M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$1.81M |
| 4 |
Apple
AAPL
|
+$1.65M |
| 5 |
Gilead Sciences
GILD
|
+$1.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 45.99% |
| 2 | Miscellaneous | 26.89% |
| 3 | Technology | 8.54% |
| 4 | Communication Services | 4.28% |
| 5 | Financials | 4.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
PUT
Merck
MRK
$358B
| $2.5M | 4.09% |
+45,483
| New | +$2.42M |
2016 Q2
0 quarters
|
|
|
2
CALL
Bristol-Myers Squibb
BMY
$118B
| $2.4M | 3.92% |
32,600
+900
| +3% | +$63.6K |
2015 Q3
3 quarters
|
|
|
AET
3
DELISTED
Aetna Inc
AET
| $2.28M | 3.72% |
18,640
+15,649
| +523% | +$1.8M |
2015 Q2
4 quarters
|
|
4
Edwards Lifesciences
EW
$49.3B
| $2.26M | 3.7% |
68,049
+6,087
| +10% | +$208K |
2014 Q4
6 quarters
|
|
|
ALDR
5
DELISTED
Alder Biopharmaceuticals
ALDR
| $1.87M | 3.06% |
75,002
+5,260
| +8% | +$142K |
2014 Q2
8 quarters
|
|
|
6
Biogen
BIIB
$34.4B
| $1.73M | 2.82% |
+7,139
| New | +$1.88M |
2016 Q2
0 quarters
|
|
|
MDCO
7
DELISTED
Medicines Co
MDCO
| $1.71M | 2.8% |
50,808
+4,470
| +10% | +$158K |
2015 Q2
4 quarters
|
|
8
PUT
Eli Lilly
LLY
$1.08T
| $1.6M | 2.62% |
+20,300
| New | +$1.53M |
2016 Q2
0 quarters
|
|
9
Meta Platforms (Facebook)
META
$1.91T
| $1.55M | 2.54% |
13,595
+7,668
| +129% | +$884K |
2013 Q4
10 quarters
|
|
10
Applied Materials
AMAT
$359B
| $1.53M | 2.5% |
63,793
+36,557
| +134% | +$806K |
2016 Q1
1 quarter
|
|
11
DELISTED
Walgreens Boots Alliance
WBA
| $1.48M | 2.41% |
17,725
-8,304
| -32% | -$670K |
2014 Q4
6 quarters
|
|
12
Jazz Pharmaceuticals
JAZZ
$13.9B
| $1.44M | 2.36% |
10,209
-5,127
| -33% | -$756K |
2015 Q1
5 quarters
|
|
13
AbbVie
ABBV
$497B
| $1.44M | 2.35% |
23,814
-22,215
| -48% | -$1.35M |
2016 Q1
1 quarter
|
|
14
PUT
State Street Health Care Select Sector SPDR ETF
XLV
$44.7B
| $1.33M | 2.17% |
+18,500
| New | +$1.3M |
2016 Q2
0 quarters
|
|
|
15
Baxter International
BAX
$12.7B
| $1.26M | 2.06% |
+27,804
| New | +$1.22M |
2016 Q2
0 quarters
|
|
|
16
McKesson
MCK
$113B
| $1.11M | 1.81% |
+5,929
| New | +$1.04M |
2016 Q2
0 quarters
|
|
|
17
UnitedHealth
UNH
$351B
| $1.09M | 1.79% |
+7,747
| New | +$1.03M |
2016 Q2
0 quarters
|
|
18
Amazon
AMZN
$2.78T
| $1.08M | 1.77% |
30,280
-13,880
| -31% | -$469K |
2015 Q4
2 quarters
|
|
19
CALL
Invesco QQQ Trust
QQQ
$493B
| $1.07M | 1.76% |
+10,000
| New | +$1.08M |
2016 Q2
0 quarters
|
|
|
DISH
20
DELISTED
DISH Network Corp.
DISH
| $1.06M | 1.74% |
+20,246
| New | +$989K |
2016 Q2
0 quarters
|
|
21
Brookdale Senior Living
BKD
$2.41B
| $1.05M | 1.71% |
67,761
+22,930
| +51% | +$400K |
2016 Q1
1 quarter
|
|
|
22
HCA Healthcare
HCA
$100B
| $1.05M | 1.71% |
13,578
-28,866
| -68% | -$2.28M |
2013 Q2
12 quarters
|
|
|
23
CALL
Applied Materials
AMAT
$359B
| $976K | 1.6% |
+40,700
| New | +$898K |
2016 Q2
0 quarters
|
|
24
CALL
State Street Materials Select Sector SPDR ETF
XLB
$7.79B
| $976K | 1.6% |
+28,600
| New | +$666K |
2016 Q2
0 quarters
|
|
25
BioMarin Pharmaceuticals
BMRN
$10.7B
| $914K | 1.5% |
+11,752
| New | +$999K |
2016 Q2
0 quarters
|
|
Similar funds
SWM
ACM
ECAU
SL
DII
FIM
EM
BHC
Partner Investment Management's Q2 2016 Portfolio in Review
As of Q2 2016, Partner Investment Management held 108 positions worth $61.1M, down 0.43% from $61.4M the previous quarter. Its ten largest holdings account for 32% of the portfolio.
Partner Investment Management withdrew a net $9.61M in Q2 2016, closing 32 positions and reducing 22 holdings. Its most notable exit was Allergan plc, an estimated $1.83M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 46% of assets, down from 52% a quarter earlier, followed by Miscellaneous and Technology.
Against the trend, Partner Investment Management opened a new position in Biogen worth $1.73M.
- Partner Investment Management's largest Q2 2016 buy was Biogen: 7,139 shares worth $1.73M.
- Partner Investment Management added most to Aetna Inc in Q2 2016, an estimated $1.8M increase.
- Partner Investment Management's biggest Q2 2016 reduction was HCA Healthcare, cutting an estimated $2.28M.
- Partner Investment Management fully exited Allergan plc in Q2 2016, selling an estimated $1.83M.
- Partner Investment Management's ten largest holdings make up 32% of its $61.1M portfolio in Q2 2016.
- Partner Investment Management opened 30 new positions and closed 32 in Q2 2016.
- Partner Investment Management's portfolio value fell 0.43% quarter-over-quarter to $61.1M.
Based on Partner Investment Management's 13F filing for Q2 2016, filed 15 Aug 2016.